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Abstract 
Extended-spectrum β-lactamase producing E. coli and K. pneumoniae is a serious threat to the 
patients. These organisms are major extended spectrum beta lactamase (ESBL) producers. The objective of 
this study was to determine the prevalence of Extended spectrum β- lactamase producing strains of 
Escherichia coli and Klebsiella spp isolates from the urine sample of children visiting International 
Friendship Children Hospital. During the seven months, between June 2016 to December 2016, 1018 mid-
stream urine samples(MSU) were collected from patients suspected of having UTI. The samples were 
investigated by conventional semi-quantitative culture technique and identification of E. coli and Klebsiella 
spp. was done by microscopy and biochemical test. Antibiotic susceptibility test of isolates was performed 
by modified Kirby Bauer Disc diffusion test. ESBL screening test was done by using 3rd generation 
Cephalosporin and confirmation done by combination disc diffusion method. Out of total 1018 MSU 
samples investigated, 200(19.64%) isolates of E. coli and 28(2.7%) isolates of Klebsiella spp. making a total of 
228(22.39%) were found to cause significant bacteriuria. 76(33.33%) isolates, from those causing significant 
bacteriuria, were Multi-drug resistant organisms. Out of 228 isolates, 54(23.68%) were ESBL producers, 
that includes 51(25.5%) Escherichia coli and 3(12.5%) Klebsiella pneumoniae. ESBL producers were more 
common in in-patient (36.17%) than out-patient (20.44%). Most of the ESBL producers were resistance to 
amoxicillin, followed by Cotrimoxazole and Ciprofloxacin respectively. They were highly sensitive to 
Imipenem, Tigecycline, Amikacin, Piperacillin-Tazobactam, and Nitrofurantoin. High prevalence of ESBL 
producing E. coli and Klebsiella pneumoniae was found among children. Regular and routine monitoring of 
ESBL producing isolates is essential. 
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Introduction 
Urinary tract infection (UTI) is a term applied to a 
variety of clinical conditions ranging in severity 
from asymptomatic which is carrier status in the 
urine to symptomatic acute infection of the kidney 
with resultant sepsis [1]. The clinical symptoms of 
UTI usually include frequency, dysuria, pyuria, 
suprapubic tenderness, back pain, fever and 
urgency [2]. The most common uropathogenic 
Gram negative bacteria are Escherichia coli and 
Klebsiella pneumoniae [3]. 
Extended-spectrum β lactamases (ESBLs) are a 
group of enzymes with the ability to hydrolyze 
and cause resistance to the oxyimino-
cephalosporins (i.e.cefotaxime, ceftazidime, 
ceftriaxone, cefuroxime and cefepime) 
monobactams (i.e. aztreonam) [4]. Beta-lactamases 
are among the most heterogeneous group of 
resistance enzymes. Despite a significant amount 
of amino acid sequence variability, beta-
lactamases share a common overall topology [5]. 
There are several ESBLs genotypes. These are 
SHV, TEM, and CTX-M [6]. Other clinically 
important genotypes include OXA, VEB, PER, 
BES-1, BEL-1, SFO-1, TLA, and IBC [7]. “Classical” 
ESBLs are derived from TEM and SHV enzymes 
whereas “Non-Classical” ESBLs are derived from 
enzymes other than TEM or SHV. 90% of 
ampicillin resistance in E. coli is due to the 
production of TEM-1 [8]. Based on different 
combinations of changes, currently, 195 TEM-type 
enzymes have been described. TEM-2, the first 
variant described, differed from TEM-1 through 
the substitution of a lysine for a glutamine at 
position 39 [6]. A shift in the distribution of 
different ESBLs has recently occurred in Europe, 
with a dramatic increase of CTX-M enzymes over 
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TEM and SHV variants [9]. Since 2000, E. coli 
producing CTX-M β-lactamases have emerged 
worldwide as an important cause of community-
onset urinary tract infections (UTIs) and this has 
been called the CTX-M pandemic [10]. These 
enzymes were named for their greater activity 
against cefotaxime than other oxyimino-beta-
lactam substrates (e.g. ceftazidime, ceftriaxone, or 
cefepime) [7]. Rather than arising from mutation, 
they represent examples of plasmid acquisition of 
beta-lactamase genes normally found on the 
chromosome of Kluyvera species, a group of rarely 
pathogenic commensal organisms [9]. In France, a 
novel derivative of OXA-10 (numbered OXA-28) 
was found in a P. aeruginosa isolate [11]. The rapid 
increasing rate of ESBL production among 
Enterobacteriaceae, mainly E. coli and Klebsiella 
pneumonia, have created a serious global public 
health problem [12]. Availability of limited 
treatment options for the infections caused ESBL 
producing bacteria makes the treatment very 
difficult and often results into treatment failure 
[13]. Scant number of studies had been reported 
from Nepal assessing the ESBL producers among 
E. coli and Klebsiella spp in children. Hence the 
study was carried out to determine the prevalence 
of ESBL producing Escherichia coli and Klebsiella 
spp isolates from the urine samples of children. 
Materials and Methodology 
Sample collection and identification of 
bacteria 
The cross-sectional study was carried out in 
Pathology Department of International Friendship 
Children Hospital, Maharajgunj, Kathmandu from 
June 2016 to December 2016. Patients under the 
age of 13 years or their guardians visiting the 
Pathology Department were directly interviewed 
for his/her clinical history during the sample 
collection. During the study period, 1018 
midstream urine samples were collected and 
processed according to the standard laboratory 
methods by Forbes et al [14].  Semi-quantitative 
culture technique was used to detect the presence 
of significant bacteriuria.  The bacterial culture 
was done on MacConkey Agar (MA) and Blood 
Agar (BA) and incubated overnight at 37oC for 
isolation of pure culture. Diagnosis of UTI was 
made when there were colony count exceeding 105 
cfu/ml of urine specimen. The isolates were 
identified based on morphology, gram’s staining, 
motility, and standard biochemical tests as 
described in Forbes et al [14]. 
Modified Kirby-Bauer’s disc diffusion method was 
employed for the antibiotic susceptibility test of 
potential pathogenic isolates as per standard 
technique on Muller Hilton Agar [15]. 
Nitrofurantoin(300mcg), Amoxicillin (30mcg), 
Cotrimoxazole (25 mcg), Ciprofloxacin (5mcg), 
Ceftriaxone (30 mcg), Ceftazidime (30 mcg), 
Gentamicin (10 mcg), Imipenem (10 mcg) and 
Meropenem (10 mcg) were used for antimicrobial 
susceptibility testing. 
Screening of ESBL producing strains of E. 
coli and K.pneumoniae 
The screening test for the production of ESBL was 
performed using both Ceftazidime (CAZ) (30μg) 
and Ceftriaxone (CTR) (30μg) disks. If the zone of 
inhibition was less than or equal to 22mm for CAZ 
and/or less than or equal to 25mm for CTR, the 
isolate was considered a potential ESBL-producer 
as recommended by CLSI [16]. 
Phenotypic confirmation of ESBL 
production 
Susceptible screened ESBL producers were 
subjected to combined disk test as recommended 
by the CLSI [16]. Combination disk method used 
for the confirmation of ESBL-producing strains in 
which CAZ (30μg), alone and in combination with 
Clavulanic acid (CA) (10μg) were used. After 
incubating overnight at 37°C, ≥ 5 mm increase in 
the zone diameter for either antimicrobial agent 
which was tested in combination with Clavulanic 
acid (CAC) versus its zone when tested alone, was 
interpreted as positive for ESBL production. 
Results  
Table 1: Microbiological profile of bacterial isolates 
S.N Bacterial isolates Number Percent 
1 Escherichia coli 200 82.30% 
2 Klebsiella pneumoniae 24 10% 
3 Klebsiella oxytoca 4 1.64% 
4 Citrobacter spp 3 1.23% 
5 Pseudomonas aeruginosa 2 0.82% 
6 Acinetobacter 2 0.82% 
7 Staphylococcus aureus 8 3.29% 
 Total 243 100% 
Out of the total 1018 mid-stream urine samples, 
243(23.87%) samples were found to have a 
significant growth. Out of 243 culture positive 
cases, Escherichia coli (200) (82%) was found to be  
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the most common isolates followed by Klebsiella 
pneumoniae (24) (10%), Klebsiella oxytoca (4) (1.65%), 
Citrobacter species (3) (1.15%), Pseudomonas 
aeruginosa (2) (0.85%), Acinetobacter species (2) 
(0.85%) and the gram positive isolates, 
Staphylococcus aureus (8) constitutes (3.30%) (Table 
1). Most of the patient were of age group 1-5 
(60.96%) followed by age <1 (18.42%) (Table 2). 
Table 2: Demographic distribution of E. coli and 
Klebsiella spp 
Age 
group 
Sex of patient Total 
Male    (%) Female (%) 
 
<1 year 12  (28%) 30      (72%) 42(18.42%) 
1-5 49  (35%) 90      (65%) 139(60.96%) 
6-10 11  (34.3%) 21    (65.6%) 32(14.03%) 
11-13 3   (20%) 12      (80%) 15(6.57%) 
Total 75 153 228 
Out of 200 E. coli isolates, 169(84.5%) isolates were 
sensitive to Nitrofurantoin followed by 
gentamycin 146(73%) and cotrimoxazole 110(55%). 
More than 30% isolates were resistant to third 
generation cephalosporins i.e Ceftriaxone and 
Ceftazidime (Table 3). 
Table 3: Antibiotic susceptibility pattern of 
Escherichia coli 
 
Antibiotics 
Susceptibility pattern (n=200) 
Sensitive 
(%) 
Intermediate 
(%) 
Resistance 
(%) 
Amoxicillin 14  (7) 23  (11.5) 163  (81.5) 
Ciprofloxacin 91  (45.5) 31   (15.5) 78    (39) 
Cotri-moxazole 110   (55) 22    (11) 68    (34) 
Nitrofurantoin 169 (84.5) 20     (10) 11    (5.5) 
Gentamycin 146  (73) 21   (10.5) 33   (16.5) 
Ceftriaxone 108  (54) 30    (15) 62     (31) 
Ceftazidime 98  (49) 34   (17) 68    (34) 
Out of total 24K. pneumoniae isolates, 19(79.2%) 
were sensitive towards Gentamycin, followed by 
Nitrofurantoin 17 (71%), Ciprofloxacin 16 (67%) 
and Ceftriaxone 16 (67%) (Table 4).  
Table 4: Antibiotic susceptibility pattern of K. 
pneumoniae isolates. 
 
Antibiotics 
                 Susceptibility pattern(n=24) 
Sensitive 
(%) 
Intermediate 
(%) 
Resistance 
(%) 
Amoxicillin 0     (0) 0     (0) 24    (100) 
Ciprofloxacin 16   (67) 4     (17) 4       (17) 
Cotrimoxazole 14   (58) 3     (13) 7       (29) 
Nitrofurantoin 17   (71) 1     (4) 6      (25) 
Gentamycin 19    (79.2) 3     (12.5) 2      (8.3) 
Ceftriaxone 16    (67) 2     (8) 6      (25) 
Ceftazidime 14    (58) 4     (17) 6      (25) 
Among total 4 K. oxytoca isolates, all 4 were 
resistant to Amoxicillin, howeversensitive to 
Nitrofurantoin., 3 (75%) of them were sensitive to 
to Cotrimoxazole, followed by ciprofloxacin. 68 
(34%) of E. coli isolates, 6(25%) of Klebsiella 
pneumoniae isolates and 2 (50%) of Klebsiella oxytoca 
isolates, making a total of 76(33.33%) isolates were 
Multi-drug resistant (Table 5). 
Table 5: Distribution of MDR isolates 
Bacterial isolates Total MDR (%) 
Escherichia coli 200 68         (34%) 
Klebsiella pneumoniae 24 6           (25%) 
Klebsiella oxytoca 4 2           (50%) 
Total 228 76(33.33%) 
Out of 228 isolates, 61 isolates gave ESBL 
screening test positive. 51 isolates of E. coli and 3 
isolates of Klebsiella pneumoniae making a total of 
54(23.68%) were confirmed as ESBL producers. 
None of K. oxytoca was ESBL producer (Table 6). 
Table 6: Detection of ESBL by combination disk 
method. 
Organism Significant 
growth 
Screening 
test 
positive 
Confirmatory 
test(combination 
disk method) 
Increase in 
diameter ≥5mm 
Escherichia 
coli 
200 57 51(25.5%) 
Klebsiella 
pneumonia 
24 4 3(12.5%) 
Klebsiella 
oxytoca 
4 - - 
Total 228 61 54(23.68%) 
 Out of 75 isolates from male, 12(16%) were ESBL 
producer and out of 153 isolates from female 
42(27.54%) were ESBL producer. More female was 
infected as compared to male, also chi-square test 
suggests a significant association in between sex of 
a patient and ESBL producers(p-value<0.05) 
(Table 7). 
Table 7: Gender wise distribution of ESBL producing 
isolates. 
Sex  ESBL 
producer 
ESBL non-
producer 
Total p-value 
Male 12(16%) 63(84%) 75 <0.05 
Female 42(27.45%) 111(72.54%) 153 
Total 54(23.68%) 174(76.31%) 228  
Among culture positive cases, 47 were from In-
patient and remaining 181 were from out-patient. 
Among 47 In-patient, 17(36.17%) was found to be 
ESBL positives. Similarly, among 181 Out-patient, 
37(20.44%) was found to be ESBL positives (Table 
8). All 51 ESBL producing isolates of E. coli were 
sensitive to Imipenem, Piperacillin-tazobactam, 
Tigecycline and Amikacin. 94.2%and 92.2% of E. 
coli were resistant to Ceftriaxone and Ceftazidime, 
respectively. 
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Furthermore, 88.2% and 31.4% of E. coli were 
resistant to Cefepime and Meropenem, 
respectively (Table 9). All of the 3 ESBL producing 
K. pneumoniae isolates were sensitive to Imipenem, 
Meropenem, Piperacillin-tazobactam, tigecycline, 
and Amikacin. All of the isolates were resistant to 
Cefepime and Amoxicillin. 
Table 9: Antibioitic susceptibility pattern of ESBL producing 
strain of E. coli 
Antibiotics E. coli (n=51) 
Sensitive Sensitive
% 
Resistance Resistance
% 
Amoxicillin - - 51 100 
Ciprofloxacin 13 25.5 38 74.5 
Cotrimoxazole 13 25.5 38 74.5 
Nitrofurantoin 48 94.1 3 5.9 
Gentamicin  32 66.7 19 37.3 
Ceftriaxone 3 5.9 48 94.1 
Ceftazidime 4 7.8 47 92.2 
Imipenem 51 100 0 0 
Meropenem 35 68.6 16 31.4 
Cefepime 6 11.8 45 88.2 
Piperacillin 51 100 - - 
Tigecycline 51 100 - - 
Amikacin 51 100 - - 
Discussion 
Out of 1018 mid-stream urine sample, 243 
(23.87%) showed significant growth.  Similar 
result was obtained by Bhandari (2013) where 
growth positivity was found to be 23.36% [17]. 
Similarly, the study carried out in India by 
Niranjan et al (2014) yielded 18.5% significant 
growth [18].  However, our result is low as 
compared to that reported from South Africa 
(51%) by Habte et al (2009) [19]. A study 
conducted in Nepal by Bhatta et al (2013), 
demonstrated similar result with 27.3% significant 
growth [20]. The rate of infection found in female 
patients was 163/684 (23.83%) and in male, the 
rate of infections was found to be 80/354 (22.59%). 
There wasn’t any huge difference between rate of 
infection in male and female children patient. This 
result is in contrast to the earlier studies by 
Thakur et al (2013) where 56.64% female and 
43.36% male patient were infected [21]. The 
growth positivity with 33.5% among female 
patients and 23.7% in male patients was observed 
in a similar study by Baral et al (2012)[22].  
The predominant isolate was E. coli (82.30%) 
followed by Klebsiella species (11.53%) and 
Staphylococcus aureus (3.29%). E. coli is a 
predominant isolate, because E. coli can bind to 
the glycol-conjugate receptor of the uroepithelial 
cells of human urinary tract so it can initiate 
infection itself. E. coli is isolated in 90% of infection 
and strains are characterized by presence of 
unique virulence determinant the pilus (Gal-Gal) 
receptor [23]. Similar result was obtained by other 
studies [24, 25]. 
E. coli was found to be resistant towards 
amoxicillin (81.5%), Co-trimoxazole (35%), and 
Ciprofloxacin (38%). In our study, 25% of K. 
pneumoniae were resistant to both Ceftriaxone and 
Ceftazidime. Other studies from Nepal reported 
that the resistance rates of K. pneumoniae to third-
generation Cephalosporin were between 20% to 
75% [26,27].  
Likewise, 25% and 8.3% of K. pneumoniae were 
found resistant to Nitrofurantoin and Gentamicin, 
respectively. All K. pneumoniae strains were 
resistant (100%) to Amoxicillin, while resistance 
rate for E. coli was 81.5%. Similar result was 
observed in a study carried out at Madagascar, 
where 80% of the E. coli isolates were resistant to 
amoxicillin [28]. In our study, E. coli showed a 
high resistance rate 68% to Co-trimoxazole 
whereas the K. pneumoniae showed resistance rate 
30% to Co-trimoxazole. A comparable resistance 
rate of 80% and 45% to Cotrimoxazole was shown 
among ESBL producing E. coli and K. pneumoniae 
isolates in a study conducted in Iran [29]. Bazzaz 
et al (2009) reported ESBL-producing isolates of K. 
pneumoniae and E. coli as 59.2% [30]. 
In this study, 17% isolates of K. pneumoniae were 
resistant to Ciprofloxacin. Resistant to 
fluoroquinolones is due to the result of alterations 
in target enzyme (DNA gyrase and topoisomerase 
IV) and because of change in drug entry and efflux 
[31]. Klebsiella pneumoniae sensitivity towards 
Gentamicin was found in 79.2% which was 
significantly higher than that was reported in 
Karanchi, Pakistan where a resistance rate for 
gentamicin was 46.7% [32]. However, the rate was 
only slightly higher than to the findings from 
previous study done in Nepal where the 
sensitivity was 72.9% [22]. These significant 
variations may be attributed to selective pressures 
Table 8: Department wise distribution of ESBL 
producers. 
 In-patients Out-patients Total p-value 
ESBL 
producer 
17(36.17%) 37(20.44%) 54 <0.05 
ESBL non-
producer 
30(63.82%) 144(79.55%) 174  
Total 47 181 228  
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by drugs in different regions. Resistance of 
aminoglycosides is done by the enzymes that 
cause modification of drug by phosphorylation, 
acetylation or adenylation and less or more by 
other methods [33]. 
 In our study, 31.4% of ESBL positive E. coli was 
resistant to Meropenem, whereas all isolates were 
sensitive to Imipenem which is similar to the 
study done in Peshawar, Pakistan [34]. The 
emergence of carbapenem resistance in K. 
pneumoniae is typically attributed to the 
production of Klebsiella pneumoniae carbapenemase 
(KPC) [35].  
We found the 76 (33.33%) isolates of E. coli and 
Klebsiella spp were multidrug resistant. Similar 
findings were observed in the study done by 
Tuladhar et al (2003), in a hospital in Kathmandu, 
where 35.21% of bacterial strain were MDR [36]. 
But the result was in contrast to the study by 
Upadhaya et al (2013) where 48% were MDR [37]. 
The prevalence of MDR varied among different 
studies and outcome of the prevalence may 
depend on various factors such as MDR criterion, 
how the antibiotics are used, and organism 
encoding multiple resistance gene which is 
becoming more prevalent.  
Out of 228 isolates, 54 (23.68%) were ESBL 
producer. Our finding was lower in comparison to 
the study conducted by Dahal et al (2016), in a 
community hospital of Kathmandu that reported 
47.75% as ESBL producer [25]. A study done in 
India reported nearly 40% of urinary isolates of E. 
coli and K. pneumoniae were ESBL positive [38]. 
Our result was similar to the study done by 
Poudyal (2010) where 25.7% ESBL producer were 
isolated from urine sample [39]. However, our 
result showed higher prevalence as compared to 
the study by Logan et al (2014) in the United States 
with ESBLs representing only 0.28% of all E. coli, 
K. pneumoniae, and P. mirabilis in children from 
1999 to 2001 and later increasing to 0.92% of all 
isolates in 2010–2011 [40]. The occurrence of ESBLs 
among clinical isolates varies greatly from country 
to country, among the hospitals, within the 
country. 
In our study, 25.5% of E. coli isolates and 12.5% of 
Klebsiella pneumoniae isolates were ESBL producer. 
These findings were comparable to the study done 
by Chander and Shrestha (2013) in Nepal tertiary 
hospital in which 13.51% of E. coli and 16.55% of 
Klebsiella pneumoniae were ESBL producers [41]. 
ESBL occurrence among E. coli and Klebsiella is of 
great concern since infections caused by these 
bacteria are very common and resistance of the 
organism may be due to the presence of capsule 
that gives some level of protection to the cells, 
presence of multidrug resistance efflux pump, 
they also spread easily, are pathogenic and 
efficient at acquiring and disseminating resistance 
plasmid [42]. More female (27.45%) were infected 
as compared to male (16%). Similar result was 
obtained by Bhandari (2013) [17].  
Though some of our results were very much 
contrast with other studies, the prevalence rate of 
ESBL producing isolates in our study was 
considered significant and high.  The higher 
number of ESBL producers might be due to more 
reliance on third generation Cephalosporins to 
treat Gram negative infections and unscrupulous 
hospital antibiotic policy. Moreover, high 
prevalence of ESBL isolates among children might 
be due to immaturity of the immune system in 
these infection in these age group. Further studies 
are required to know the current burden in these 
population. 
Conclusion 
High prevalence of ESBL producing E. coli and K. 
pneumoniae was observed in our study. 
E. coli is predominant ESBL producers than K. 
pneumoniae. Children under age five were found to 
be highly infected with urinary tract infection. 
Escherichia coli and Klebsiella spp are emerging 
highly as a multi-drug resistant. Imipenem, 
Tigecycline, Amikacin, Piperacillin-Tazobactam 
were found to be the most effective drug against 
the ESBL producing isolates. Nitrofurantoin and 
Gentamycin can be used as a drug of choice 
against non-ESBL producing isolates.  
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